In the present study, we prepared and characterized a novel nano-delivery system for the oral administration of a natural MDM2 inhibitor, GS25, and evaluated its pharmacokinetics, toxicity, and efficacy in preclinical models of human prostate cancer. The gene discussed is MDM2; the disease is prostate cancer.